These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 22225620)
1. Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial. Emu B; Luca D; Offutt C; Grogan JL; Rojkovich B; Williams MB; Tang MT; Xiao J; Lee JH; Davis JC Arthritis Res Ther; 2012 Jan; 14(1):R6. PubMed ID: 22225620 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study). Kennedy WP; Simon JA; Offutt C; Horn P; Herman A; Townsend MJ; Tang MT; Grogan JL; Hsieh F; Davis JC Arthritis Res Ther; 2014 Oct; 16(5):467. PubMed ID: 25359150 [TBL] [Abstract][Full Text] [Related]
3. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493 [TBL] [Abstract][Full Text] [Related]
4. A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis. Cohen S; Beebe JS; Chindalore V; Guan S; Hassan-Zahraee M; Saxena M; Xi L; Hyde C; Koride S; Levin R; Lubaczewski S; Salganik M; Sloan A; Stevens E; Peeva E; Vincent MS; Martin DA; Chu M Arthritis Res Ther; 2024 Jun; 26(1):117. PubMed ID: 38845046 [TBL] [Abstract][Full Text] [Related]
5. A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis. Martin DA; Churchill M; Flores-Suarez L; Cardiel MH; Wallace D; Martin R; Phillips K; Kaine JL; Dong H; Salinger D; Stevens E; Russell CB; Chung JB Arthritis Res Ther; 2013 Oct; 15(5):R164. PubMed ID: 24286136 [TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti- oncostatin M monoclonal antibody in rheumatoid arthritis: results from phase II randomized, placebo-controlled trials. Choy EH; Bendit M; McAleer D; Liu F; Feeney M; Brett S; Zamuner S; Campanile A; Toso J Arthritis Res Ther; 2013 Sep; 15(5):R132. PubMed ID: 24286335 [TBL] [Abstract][Full Text] [Related]
7. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Burmester GR; Rubbert-Roth A; Cantagrel A; Hall S; Leszczynski P; Feldman D; Rangaraj MJ; Roane G; Ludivico C; Lu P; Rowell L; Bao M; Mysler EF Ann Rheum Dis; 2014 Jan; 73(1):69-74. PubMed ID: 23904473 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial. Taylor PC; Saurigny D; Vencovsky J; Takeuchi T; Nakamura T; Matsievskaia G; Hunt B; Wagner T; Souberbielle B; Arthritis Res Ther; 2019 Apr; 21(1):101. PubMed ID: 30999929 [TBL] [Abstract][Full Text] [Related]
9. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Huizinga TW; Fleischmann RM; Jasson M; Radin AR; van Adelsberg J; Fiore S; Huang X; Yancopoulos GD; Stahl N; Genovese MC Ann Rheum Dis; 2014 Sep; 73(9):1626-34. PubMed ID: 24297381 [TBL] [Abstract][Full Text] [Related]
10. Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Ogata A; Tanimura K; Sugimoto T; Inoue H; Urata Y; Matsubara T; Kondo M; Ueki Y; Iwahashi M; Tohma S; Ohta S; Saeki Y; Tanaka T; Arthritis Care Res (Hoboken); 2014 Mar; 66(3):344-54. PubMed ID: 23983039 [TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study. Weinblatt ME; Mease P; Mysler E; Takeuchi T; Drescher E; Berman A; Xing J; Zilberstein M; Banerjee S; Emery P Arthritis Rheumatol; 2015 Oct; 67(10):2591-600. PubMed ID: 26138593 [TBL] [Abstract][Full Text] [Related]
12. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Fleischmann R; Cutolo M; Genovese MC; Lee EB; Kanik KS; Sadis S; Connell CA; Gruben D; Krishnaswami S; Wallenstein G; Wilkinson BE; Zwillich SH Arthritis Rheum; 2012 Mar; 64(3):617-29. PubMed ID: 21952978 [TBL] [Abstract][Full Text] [Related]
13. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Kivitz A; Olech E; Borofsky M; Zazueta BM; Navarro-Sarabia F; Radominski SC; Merrill JT; Rowell L; Nasmyth-Miller C; Bao M; Wright S; Pope JE Arthritis Care Res (Hoboken); 2014 Nov; 66(11):1653-61. PubMed ID: 24942540 [TBL] [Abstract][Full Text] [Related]
14. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195 [TBL] [Abstract][Full Text] [Related]
15. Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic Lupus. Cohen S; Clowse M; Pardo P; Bhattacharya I; Menon S; Gourley I; Diehl A Clin Ther; 2016 Jun; 38(6):1417-1434.e2. PubMed ID: 27112532 [TBL] [Abstract][Full Text] [Related]
16. [Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study.]. Huang F; Zhang FC; Bao CD; Tao Y; Gu JR; Xu JH; Zhu P; Xu HJ; Zhang ZY; Zhao DB; Wu DH Zhonghua Nei Ke Za Zhi; 2009 Nov; 48(11):916-21. PubMed ID: 20079321 [TBL] [Abstract][Full Text] [Related]
17. The role of lymphotoxin-α in rheumatoid arthritis. Hirose T; Fukuma Y; Takeshita A; Nishida K Inflamm Res; 2018 Jun; 67(6):495-501. PubMed ID: 29541795 [TBL] [Abstract][Full Text] [Related]
18. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Genovese MC; Van den Bosch F; Roberson SA; Bojin S; Biagini IM; Ryan P; Sloan-Lancaster J Arthritis Rheum; 2010 Apr; 62(4):929-39. PubMed ID: 20131262 [TBL] [Abstract][Full Text] [Related]
19. A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Yellin M; Paliienko I; Balanescu A; Ter-Vartanian S; Tseluyko V; Xu LA; Tao X; Cardarelli PM; Leblanc H; Nichol G; Ancuta C; Chirieac R; Luo A Arthritis Rheum; 2012 Jun; 64(6):1730-9. PubMed ID: 22147649 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Genovese MC; Fleischmann R; Furst D; Janssen N; Carter J; Dasgupta B; Bryson J; Duncan B; Zhu W; Pitzalis C; Durez P; Kretsos K Ann Rheum Dis; 2014 Sep; 73(9):1607-15. PubMed ID: 24641941 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]